Feeds:
Posts
Comments

Posts Tagged ‘Johns Hopkins’

JOHNS HOPKINS: Thalidomide may play a role in the treatment of advanced prostate cancer, according to a new study reported in The Journal of Urology. READ MORE>

Read Full Post »

URO TODAY: Cholesterol levels and prostate cancer definitely seem to be connected, a new study at Johns Hopkins in Baltimore has revealed. READ MORE>

Our study supports two prior ones suggesting that cholesterol influences risk of high-grade prostate cancer, and indirectly supports the hypothesis that cholesterol-lowering is a mechanism by which statins are protective.

Read Full Post »

NEW PROSTATE CANCER INFOLINK: Evidence is growing that active surveillance – watchful waiting – is a viable option for men diagnosed with prostate cancer, but more long-term data is needed on survival rates. READ MORE>

“…these data – indicating that just 51 (11%) of 470 men in the Johns Hopkins active surveillance series have gone on to have a radical prostatectomy within roughly a 3-year follow-up period – continue to offer strong evidence of the potential of this management technique.

Read Full Post »

URO TODAY: Cox-2 cancer inhibitor celecoxib made no difference to 137 prostate cancer patients in a trial at the Johns Hopkins Cancer Centre in Baltimore. READ MORE>

Cyclooxygenase-2 (COX-2) is a potential pharmacologic target for the prevention of various malignancies, including prostate cancer.

We conducted a randomised, double-blind trial to examine the effect of on drug-specific biomarkers from prostate tissue obtained at prostatectomy.

Treatment with four to six weeks of celecoxib had no effect on intermediate biomarkers of prostate carcinogenesis…

We caution against using celecoxib 400 mg twice daily as a preventive agent for prostate cancer in additional studies.

Read Full Post »

NEW PROSTATE CANCER INFOLINK: Jonathon Epstein, MD, at Johns Hopkins is widely considered to be one of the pre-eminent prostate cancer pathologists in the world today, so it is worth listening when he says that the Gleason grading system needs revision. READ MORE>

Read Full Post »

PITTSBURGH TRIBUNE-REVIEW: A Johns Hopkins researcher and the University of Pittsburgh committed more than five years of prostate cancer research fraud, a privately owned biotechnology company alleges in a lawsuit. READ MORE>

Read Full Post »

JULY 4: SCIENCE DAILY: Cancer experts at Johns Hopkins say a study tracking 774 prostate cancer patients for a median of eight years has shown that a three-way combination of measurements has the best chance yet of predicting disease metastasis. READ MORE>

The new prediction method comprises the length of time it takes for PSA (prostate-specific antigen) to double, Gleason score (a numeric indicator of prostate cancer aggressiveness as seen under the microscope), and the interval between surgical removal of the prostate and the first detectable PSA level.

According to Johns Hopkins investigators, combining these three measurements more accurately estimates risk that the cancer has spread than do other methods and should help determine which patients may benefit from additional therapy when PSA levels rise after surgery to remove the prostate.

Read Full Post »

Older Posts »